<DOC>
	<DOCNO>NCT02698852</DOCNO>
	<brief_summary>PIONEER-II OPC trial prospective , multicenter , single-arm registry trial . 1000 subject approximately 40 interventional cardiology center enrol evaluate target lesion failure ( TLF ) primary endpoint 1 year . And subject follow 5 year attain data secondary endpoint .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety BuMA Supreme Drug Eluting Stent ( DES )</brief_title>
	<detailed_description>Realizing even uniform complete endothelial coverage , BuMA Supreme™ biodegradable drug coat coronary stent system comprise new generation biodegradable drug elute stent development Sino medical science ( SINOMED ) . BuMA Supreme™ reconfigures BuMA™ DES utilizing high caliber cobalt chromium platform coat rapidly degrade PLGA scaffold .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>1 . Age 1875 , male nonpregnant female 2 . Evidence nonsymptomatic ischemia , stable nonstable angina pectoris past MI 3 . Target lesion primary denovo coronary artery disease 4 . The target lesion length ≤ 60 mm , diameter 2.25mm－5.0mm ( visually estimate ) 5 . Lesion diameter stenosis ≥70 % ( visually estimate ) 6 . For target lesion , stent implantation 7 . Acceptable candidate Coronary Artery Bypass Grafting ( CABG ) 8 . Understand study purpose , willing participate sign letter consent , agree followup visit include 9 month angiographic followup 1 . Acute MI within 1 week 2 . Chronic total occlusion ( TIMI 0 ) , leave main lesion , interventionrequired threevessel lesion , branch vessel diameter ≥ 2.5mm bypass lesion 3 . More 3 stent require 4 . Patients refuse implanted stent 5 . Calcified lesion fail predilation , twisted lesion lesion unsuitable stent delivery expansion 6 . Instent restenosis 7 . Planned percutaneous coronary intervention ( PCI ) within 3 month post procedure 8 . Other stent implant within 1 year 9 . Severe heart failure ( NYHA III ) leave ventricle ejection fraction ( EF ) &lt; 40 % 10 . Renal function damage , blood creatinine &gt; 176.82 μmol/L 11 . Bleeding tendency , active peptic ulcer disease , cerebral subarachnoid hemorrhage , cerebral apoplexy within half year contraindication antiplatelet anticoagulation agent 12 . Allergic drug agent use stent protocol ( PLGA , sirolimus , aspirin , clopidogrel , contrast agent , cobalt , nickel , chromium , iron , wolfram et . al . ) 13 . Life expectation &lt; 12 month 14 . Have reach primary end point participate trial 15 . Poor compliance protocol 16 . Heart implantation case</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Interventional Cardiology</keyword>
</DOC>